Summary of the invention
One of purpose of the present invention is to be provided for the probe sequence of EGFR detection in Gene Mutation.
The technical scheme that realizes above-mentioned purpose is as follows:
The probe that is used for the EGFR detection in Gene Mutation: include
Be selected from SEQ ID NO.1~SEQ ID NO.3 any, at the wild-type probe of Exon19 exon, and be selected from SEQ ID NO.4~SEQ ID NO.6 any, at del E746-A750 (1) the mutant probe of Exon19 exon, and/or be selected from SEQ ID NO.29~SEQ ID NO.31 any, at mutant del E746-A750 (2) probe of Exon19 exon; And/or
Be selected from SEQ ID NO.7~SEQ ID NO.9 any at the wild-type probe of Exon21 exon and be selected from any mutant probe of SEQ ID NO.10~SEQ ID NO.12 at the Exon21 exon.
Another object of the present invention provides the liquid-phase chip of EGFR detection in Gene Mutation.This liquid-phase chip can be used for detecting the relevant sudden change on EGFR gene 19 and 21 exons, thereby can be used for predicting Gefitinib, and sieve in distress waits the pharmacological agent curative effect for Buddhist nun.
The technical scheme that realizes above-mentioned purpose is as follows:
A kind of liquid-phase chip of EGFR detection in Gene Mutation, mainly include: be coated with base sequence be selected from SEQ IDNO.1~SEQ ID NO.3 any, microballoon at the amido modified probe of Exon19 exon wild-type, and be coated with base sequence be selected from SEQ ID NO.4~SEQ ID NO.6 any, at the microballoon of the amido modified probe of Exon19 exon delE746-A750 (1) mutant, and/or be coated with base sequence be selected from SEQ ID NO.29~SEQ ID NO.31 any, microballoon at the amido modified probe of Exon19 exon del E746-A750 (2) mutant; And/or
Be coated with base sequence and be selected from any microballoon of SEQ ID NO.7~SEQ ID NO.9 at the amido modified probe of Exon21 exon wild-type, with be coated with base sequence and be selected from any microballoon of SEQ ID NO.10~SEQ ID NO.12 at the amido modified probe of Exon21 exons mutation type, be connected with spacerarm between the base sequence of above-mentioned every kind of probe and the amino, above-mentioned every kind of microballoon has the different colours coding;
And the primer that is used to amplify the target sequence with 19 exons and/or 21 exons mutation sites, and the end of this target sequence has biotin labeling.
The above spacerarm is to be used for specific probe and microsphere surface is spaced apart or specific probe is placed the sequence of hydrophilic environments.By the spacerarm sequence of suitable length is set between probe sequence and amino, can reduce sterically hinderedly, improve the efficient of hybridization and the specificity of hybridization.Common spacerarm sequence comprises poly dT, i.e. poly (dT), and oligomerization four polyoxyethylene glycol and (CH2) n spacerarm (n 〉=3) are as (CH2) 12, (CH2) 18 etc.In addition, if exist poly (dA) to disturb, can also use poly (TTG) as spacerarm.Spacerarm of the present invention is preferably 5-30 T, more preferably 10 T.
Composition SEQ ID NO. with amido modified probe of spacerarm
5’NH2-TTTTTTTTTTcaaggaattaagagaagcaacat3’ 1
5’NH2-TTTTTTTTTTaa
ggaattaagagaagcaac3’ 2
5’NH2-TTTTTTTTTTgttgcttctcttaattcctt3’ 3
5’NH2-TTTTTTTTTTgtcgctatcaaaacatctccg3’ 4
5’NH2-TTTTTTTTTTtcgctatc
aaaacatctccg3’ 5
5’NH2-TTTTTTTTTTcggagatgttttgatagcga3’ 6
5’NH2-TTTTTTTTTTagattttgggcTggccaaact3’ 7
5’NH2-TTTTTTTTTTgattttgggcTggccaaact3’ 8
5’NH2-TTTTTTTTTTagtttggccAgcccaaaatc3’ 9
5’NH2-TTTTTTTTTTtttgggcGggccaaactctg3’ 10
5’NH2-TTTTTTTTTTgattttgggcGggccaaact3’ 11
5’NH2-TTTTTTTTTTagtttggccCgcccaaaatc3’ 12
5’NH2-TTTTTTTTTT ccgtcgctatcaagacatctc3’ 29
5’NH2-TTTTTTTTTT cgtcgctatcaagacatct3’ 30
5’NH2-TTTTTTTTTT gagatgtcttgatagcgacgg3’ 31。
Preferably, the primer that is used to amplify the target sequence with 19 exons mutation sites includes SEQ ID NO.13~SEQ ID NO.15 primer sequence, has at least one to have terminal biotin labeling in the described primer; And/or be used to amplify the SEQ ID NO.16~SEQ ID NO.18 primer of target sequence with 21 exons mutation sites, have at least one to have terminal biotin labeling in the described primer.
Another object of the present invention also is to provide a kind of detection method of EGFR transgenation, this method is quick, accurate, easy and simple to handle, a plurality of mutational sites of parallel detection simultaneously, and sample to be tested can be a tissue samples, can also be serum, blood plasma or hydrothorax.
A kind of detection method of using the liquid-phase chip EGFR transgenation of above-mentioned EGFR detection in Gene Mutation may further comprise the steps:
(1) behind the DNA in the extraction sample to be detected, carries out first round pcr amplification with the primer that is used to amplify target sequence with 19 exons and/or 21 exons mutation sites;
(2) enzyme is cut enrichment first round pcr amplification product;
(3) cutting product with enzyme is that template is carried out second and taken turns pcr amplification;
(4) second take turns pcr amplification product and the above-mentioned microballoon that is coated with probe sequence is hybridized;
(5) add Streptavidin-phycoerythrin behind the hybridization and react, then by Luminex instrument detecting signal.
Preferably, carry out primer that first round pcr amplification uses to being: SEQ ID NO.13, SEQ ID NO.14 and/or SEQID NO.16, SEQ ID NO.17.
Carrying out second, to take turns the primer that pcr amplification uses right: SEQ ID NO.13, SEQ ID NO.15 and/or SEQ ID NO.18, SEQ ID NO.17.
Preferably, the temperature of hybridization is 55-60 ℃.
Preferably, every kind of preparation method who is coated with the microballoon of probe comprises that step is as follows:
(1) get the microballoon mother liquor, vortex fully is mixed into the microballoon suspension;
(2) take out 8 μ l microballoon mother liquors, contain 0.8 * 10 altogether
5-1.2 * 10
5Individual microballoon is to the 0.5ml centrifuge tube;
The centrifugal 10min of (3) 15,000rpm, careful abandoning supernatant;
(4) add 10 μ l coupling liquid (pH4.5), vortex makes it abundant mixing;
(5) add 2pmol/ μ l probe working fluid 2 μ l;
(6) the EDC working fluid of adding 2.5 μ l 10mg/ml is hatched 30min for 25 ℃; Repeat this step once;
(7) add the 0.2ml washings, vortex makes it abundant mixing, and 12, the centrifugal 5min of 000g, careful abandoning supernatant; Repeat this step once;
(8) add 500 μ lTE solution, vortex makes it abundant mixing;
The centrifugal 5min of (9) 12,000g, careful abandoning supernatant;
(10) add 17 μ lTE solution, vortex makes it abundant mixing, and microballoon concentration should be about 5 * 10
3Individual/μ l;
(11) get 2 μ l, 50 times of dilute with waters, counting is stored in 2-8 ℃.
Major advantage of the present invention is:
(1) adopts EGFR gene mutation detection liquid-phase chip provided by the invention, can detect the higher site of EGFR transgenation relative frequency simultaneously, can each detects separately to 19 exons and 21 exons, also can both detect simultaneously, reaction conditions homogeneous during detection, the detected result specificity is good, and is highly sensitive, and accuracy in detection reaches more than 90%.
(2) detection method step of the present invention is simple, thereby has avoided many uncertain factors of existing in the complex operations process, thereby can improve the detection accuracy rate greatly.
(3) the needed time of detection method provided by the present invention meets clinical needs especially well below sequencing technologies commonly used.
(4) the present invention's method of adopting enzyme to cut enrichment is carried out the pcr amplification of target sequence and then is used for detecting, and has avoided a large amount of wild-type sequences in the product to interference that detected result caused.
(5) detection method provided by the present invention can not only detect the EGFR transgenation in the tumor tissues sample, also can detect simultaneously the EGFR transgenation in the tumour patient body fluid, thereby has that sampling is convenient, painful little, a advantage that can dynamic monitoring of patient.
Embodiment
With the carrier of polystyrene microsphere, as detection platform, nucleic acid molecule is carried out high-throughout many indexs parallel detection with fluorescence detector as reaction.In the manufacturing processed of microballoon, mix the ruddiness and the infrared light staining agent of different ratios, thereby form the microballoon of 100 kinds of different colours codings of as many as.Different microballoon covalent attachment at the nucleic acid molecule of difference thing to be detected as probe molecule, reporter molecules is with biotin labeling, and uses high-sensitive fluorescent dyeing.These microballoons and determinand, reporter molecules, fluorescent marker just form complete microballoon detection architecture and are used for reading of Luminex system.Excitated red respectively laser of Luminex reading system and green laser are used for the detection of microsphere system, and wherein red laser detects the red classification of microsphere surface intensity of fluorescence, and according to different color in the microballoon and number class, thereby determine the type of reaction; Green laser detects the fluorescence intensity of fluorescent marker in the sample, detects microballoon kind, quantity by machine and computer automatic statistical analysis laser again, thereby judges sample to be tested plurality of target tester concentration separately.
Solution formula:
Coupling liquid (pH4.5): 0.1mol/L MES (Sigma M-2933)
Washings: 0.2ml/LTween-20 (Sigma P-9416), 1g/L SDS (SigmaL-4390)
TE (pH8.0) (storage liquid): 10mmol/L Tris (Sigma337501), 1mmol/L EDTA (Sigma E-5134) 2 * Tm hybridization buffer
Reagent |
The source |
Final concentration |
The consumption of every 250ml |
1MTris-HCl,pH8.0 |
SigmaT3038 |
0.2M |
50ml |
5MNaCl |
Sigma S5150 |
0.4M |
20ml |
Triton X-100 |
Sigma T8787 |
0.16% |
0.4ml |
Be stored in 4 ℃ after the filtration
1 * Tm hybridization buffer
Reagent |
The source |
Final concentration |
The consumption of every 250ml |
1MTris-HCl,pH8.0 |
SigmaT3038 |
0.1M |
25ml |
5MNaCl |
Sigma S5150 |
0.2M |
10ml |
Triton X-100 |
Sigma T8787 |
0.08% |
0.2ml |
Be stored in 4 ℃ after the filtration.
Embodiment 1
The preparation of the liquid-phase chip of EGFR detection in Gene Mutation
One, probe sequence design and microballoon bag quilt
Wild-type and mutant sequence at EGFR gene 19,21 exons design special oligonucleotide probe.5 ' end of probe is an amino group, then is the spacerarm of 10 T.Probe is synthetic by Shanghai Sangon Biological Engineering Technology And Service Co., Ltd.Probe is coupled at (bag is by process) with the microballoon (available from Luminex company) of different colours coding by covalent attachment respectively.Probe sequence is as shown in the table:
The concrete steps of every kind of microballoon bag quilt are as follows:
(1) with probe dry powder 10, the centrifugal 1min of 000rpm;
(2) use ddH
2O is dissolved to 0.1mM (0.1nmol/ μ l, about 70 μ l);
(3) centrifugal in short-term solution is gathered managed the end;
(4) be packed as 10 μ l and 2 μ l, be stored in-20 ℃;
(5) get the microballoon mother liquor, vortex fully is mixed into the microballoon suspension;
(6) take out 1 * 10 respectively
5Microballoon (totally 8 μ l mother liquors) is to the 0.5ml centrifuge tube;
The centrifugal 10min of (7) 15,000rpm, careful abandoning supernatant;
(8) add 10 μ l coupling liquid (pH4.5), vortex makes it abundant mixing;
(9) get 2 μ l probe mother liquors, be diluted to 2pmol/ μ l with coupling liquid (pH4.5);
(10) in the centrifuge tube that microballoon is housed, add corresponding 2pmol/ μ l probe working fluid 2 μ l;
(11) use ddH
2O prepares EDC working fluid (10mg/ml);
(12) each reaction tubes respectively adds 2.5 μ l EDC working fluids, and remaining EDC working fluid is abandoned;
Hatch 30min for (13) 25 ℃;
(14) each reaction tubes respectively adds 2.5 μ l EDC working fluids again;
Hatch 30min for (15) 25 ℃;
(16) add the 0.2ml washings, vortex makes it abundant mixing;
The centrifugal 5min of (17) 12,000g, careful abandoning supernatant;
(18) repeating step (16), (17) are once;
(19) add 500 μ lTE solution (pH8.0), vortex makes it abundant mixing;
The centrifugal 5min of (20) 12,000g, careful abandoning supernatant;
(21) add 17 μ l TE solution (pH8.0), vortex makes it abundant mixing.(microballoon concentration should be about 5 * 10
3Individual/μ l);
(22) get 2 μ l, 50 times of dilute with waters, counting;
(23) be stored in 2-8 ℃.
Two, the microballoon bag is by the detection of effect
19 exons and 21 exons are provided with 6 groups of experiments respectively.With 19 exons is example, and the microballoon bag is contained wild-type probe bag quilt in the effect detection first group reaction system microballoon is E19w-P+E19w-b with wrapping the biotin labeled reverse complementary sequence of being used by effect detection accordingly; The microballoon that contains wild-type probe bag quilt in the second group reaction system, the microballoon of mutant probe bag quilt and the reverse complementary sequence of biotin labeled wild-type probe are E19w-P+E19m-P+E19w-b; Containing the microballoon of mutant probe bag quilt and the reverse complementary sequence of biotin labeled wild-type probe in the 3rd group reaction system is E19w-P+E19m-b; Containing the microballoon of mutant probe bag quilt and the reverse complementary sequence of biotin labeled mutant probe in the 4th group reaction system is E19m-P+E19m-b; The microballoon that contains mutant probe bag quilt in the 5th group reaction system, the microballoon of wild-type probe bag quilt and the reverse complementary sequence of biotin labeled mutant probe are E19w-P+E19m-P+E19m-b; Containing the microballoon of mutant probe bag quilt and the reverse complementary sequence of biotin labeled wild-type probe in the 6th group reaction system is E19m-P+E19w-b.The microballoon bag of 21 exons is by effect detection experimental design 19 exons together.The concrete operations flow process is as follows:
(1), makes the abundant mixing of microballoon with microballoon pipe vortex;
(2) with 1.5 * Tm hybridization solution microballoon is diluted to 75/μ l (every reaction needs microballoon working fluid 33 μ l);
(3) microballoon working fluid vortex is made it abundant mixing;
(4) every hole adds 33 μ l microballoon working fluids;
(5) with TE (pH8.0) will wrap the biotin labeled probe reverse complementary sequence used by effect detection (be E19w-b, E19m-b, E21w-b E21m-b) is diluted to 25fmol/17 μ l;
(6) the background hole adds 17 μ l TE (pH8.0);
(7) other every holes add respectively the biotin labeled probe reverse complementary sequence that 17 μ l bag used by effect detection (be E19w-b, E19m-b, E21w-b, E21m-b) working fluid (being dissolved in TE solution);
(8) mixing gently;
(9) covering Sptting plate (pipe lid) avoids evaporating;
(10) PCR instrument program is set: 95 ℃ of 3min; 15min is hatched in 60 ℃ of hybridization;
(11) with 1 * Tm hybridization solution preparation SA-PE to 10ug/ml;
(12) every hole adds 25 μ l SA-PE, mixings gently;
5min is hatched in (13) 60 ℃ of hybridization;
(14) the Luminex instrument is set to hybridization temperature, reading.
The microballoon bag is as follows by the effect detection result
19 exons |
MFI |
21 exons |
MFI |
E19w-P+E19w-b |
3777 |
E21w-P+E21w-b |
3368 |
E19w-P+E19m-P+E19w-b |
2860 |
E21w-P+E21m-P+E21w-b |
4674.5 |
E19w-P+E19m-b |
5 |
E21w-P+E21m-b |
92 |
E19m-P+E19m-b |
6866.5 |
E21m-P+E21m-b |
5657 |
E19w-P+E19m-P+E19m-b |
5011 |
E21w-P+E21m-P+E21m-b |
5932 |
E19m-P+E19w-b |
0 |
E21m-P+E21w-b |
425 |
Experimental result shows, the 19 exon wild-type probe that the present invention is designed, and 19 exons mutation type probes, 21 exon wild-type probe, 21 exons mutation type probes all can be discerned corresponding complementary sequence well, and the fluorescent value after the hybridization is all more than 2500.Simultaneously, there is not cross reaction between 19 exon wild-type probe and the 19 exons mutation type probes; Have the part cross reaction between 21 exon wild-type probe and the 21 exons mutation type probes, but cross reacting rate does not influence detected result basically in 10%.
Primer design and mark
Gene order at EGFR gene 19 and 21 exons, design following primer respectively:
The primer title |
SEQIDNO |
Primer sequence (5 ' → 3 ', bp) |
Size (bp) |
Exon19-S1 |
13 |
F:ATCCCAGAAGGTGAGAAAGATAAAATTC |
Sudden change: 123 is wild: 138 |
Exon19-As1 |
14 |
R:CCTGAGGTTCAGAGCCATGGA |
Exon19-S1 |
13 |
F:ATCCCAGAAGGTGAGAAAGATAAAATTC |
Sudden change: 100 is wild: 115 |
Exon19-As2 |
15 |
R:ACCCCCACAGCAAAGCAG |
Exon21-S1 |
16 |
F:CAGCCAGGAACGTACTGGTGA |
Be 157 |
Exon21-As1 |
17 |
R:TCCCTGGTGTCAGGAAAATGCT |
Exon21-S2 |
18 |
F:CGCAGCATGTCAAGATCACAGAT |
Be 130 |
Exon21-As1 |
17 |
R:TCCCTGGTGTCAGGAAAATGCT |
Primer is given birth to worker's biotechnology company limited by Shanghai and is synthesized.Wherein, Exon19-S1 and Exon19-As1 are used for the first round pcr amplification of 19 exons, and biotin labeling Exon19-S1 and Exon19-As2 are used for second of 19 exons and take turns pcr amplification; Exon21-S1 and Exon21-As1 are used for the first round pcr amplification of 21 exons, and Exon21-As1 and biotin labeled Exon21-S2 are used for second of 21 exons and take turns pcr amplification.
The liquid-phase chip of the EGFR detection in Gene Mutation for preparing includes:
Be coated with SEQ ID NO.3's, microballoon at the amido modified probe of wild-type of Exon19 exon, be coated with SEQID NO.6's, microballoon at the amido modified probe of del E746-A750 (1) mutant of Exon19 exon, be coated with SEQID NO.31's, microballoon at the amido modified probe of del E746-A750 (2) mutant of Exon19 exon, be coated with microballoon at the amido modified probe of wild-type of Exon21 exon in SEQ ID NO.9, with the microballoon at the amido modified probe of mutant of Exon21 exon that is coated with SEQ ID NO.12, above-mentioned every kind of microballoon has the different colours coding; And
The primer sequence of SEQ ID NO.13-15 and SEQ ID NO.16-18, wherein 5 ' of SEQ ID NO.13 and SEQ IDNO.18 base sequence end adds biotin labeling respectively.
Embodiment 2
The liquid-phase chip of the EGFR detection in Gene Mutation among the utilization embodiment 1 is to the detection of nonsmall-cell lung cancer serum sample
One, the preparation of sample to be tested (extraction of the free nucleic acid of blood plasma, serum and hydrothorax supernatant):
Extract the test kit explanation in a small amount with reference to AxyPrep whole blood genome, detailed step is as follows:
(1) get the about 2.5ml of patient's anti-freezing venous blood or hydrothorax, centrifugal 15 minutes of 3000rpm gets 300 μ l supernatants and is added in the clean aseptic centrifuge tube of a 1.5ml;
(2) in centrifuge tube, add 500 μ l AP1 damping fluids, the vortex abundant mixing that vibrates;
(3) add 100 μ l AP2 damping fluids, the vortex abundant mixing that vibrates;
(4) under the room temperature 12, centrifugal 10 minutes of 000rpm;
(5) carefully draw supernatant and add among the adsorption column AxyPrep that is placed on the 2ml collection tube, cover lid, with 6, centrifugal 1 minute of 000rpm;
(6) outwell waste liquid in the waste collection pipe, with 800 μ l damping fluid W1 washing 1 time, with 6, centrifugal 1 minute of 000rpm;
(7) outwell waste liquid in the waste collection pipe, add 800 μ l damping fluid W2, with 12, centrifugal 1 minute of 000rpm; Outwell the waste liquid in the waste collection pipe, add 500 μ l damping fluid W2, with 12, centrifugal 1 minute of 000rpm discards waste liquid;
(8) adsorption column AxyPrep is put back in the sky collection tube, 12, centrifugal 1 minute of 000rpm;
(9) adsorption column AxyPrep is placed a clean aseptic 1.5ml centrifuge tube, add 40 μ l TE damping fluids, placed 1 minute under the room temperature, 12, centrifugal 1 minute eluted dna of 000rpm, electrophoresis detection ,-20 ℃ of preservations.
Two, the pcr amplification of testing sample and enzyme are cut enrichment:
(1) pcr amplification of sample DNA and enzyme are cut enrichment
It is as follows that the enzyme of exons 19 mutants is cut the enrichment pcr amplification:
1. first round pcr amplification
The PCR reaction system:
The PCR reaction conditions:
Step temperature-time cycle index
Pre-95 ℃ of 5min 1 of sex change
95 ℃ of 30sec of sex change
60 ℃ of 30sec 30 of renaturation
Extend 72 ℃ of 45sec
Extend 72 ℃ of 10min 1 at last
2.PCR product Mse I enzyme is cut:
Reaction system is as follows:
10×Mse I Buffer 1μl
PCR product 3 μ l
100×BSA 0.1μl
Mse I 0.5μl(50U/μl)
Add sterilization distilled water to 10 μ l
37 ℃ of incubations 2 hours, 65 ℃ of 20 minutes inactivators.
3. second take turns pcr amplification
The PCR reaction system:
The PCR reaction conditions:
Step temperature-time cycle index
Pre-95 ℃ of 5min 1 of sex change
95 ℃ of 30sec of sex change
60 ℃ of 30sec 30 of renaturation
Extend 72 ℃ of 45sec
Extend 72 ℃ of 10min 1 at last
It is as follows that the enzyme of exon 21 mutant is cut the enrichment pcr amplification:
1. first round pcr amplification
The PCR reaction system:
The PCR reaction conditions:
Step temperature-time cycle index
Pre-95 ℃ of 5min 1 of sex change
95 ℃ of 30sec of sex change
60 ℃ of 30sec 30 of renaturation
Extend 72 ℃ of 45sec
Extend 72 ℃ of 10min 1 at last
2.PCR product Msc I enzyme is cut:
Reaction system is as follows:
10×Msc I Buffer 1μl
PCR product 3 μ l
Msc I 0.5μl(10U/μl)
Add no enzyme water to 10 μ l
37 ℃ of incubations 2 hours, 65 ℃ of 20 minutes inactivators.
3. second take turns pcr amplification
The PCR reaction system:
The PCR reaction conditions:
Step temperature-time cycle index
Pre-95 ℃ of 5min 1 of sex change
95 ℃ of 30sec of sex change
60 ℃ of 30sec 30 of renaturation
Extend 72 ℃ of 45sec
Extend 72 ℃ of 10min 1 at last
Perhaps carry out the synchronous amplification (multiplex PCR amplification) of EGFR gene 19,21 exons mutation types and wild-type sequence
1.19 exon, 21 exon first round pcr amplifications and enzyme are cut same as described above, and different is second takes turns the method that pcr amplification is taked synchronous amplification.
2. second take turns pcr amplification (19,21 exon wild-type sequences and mutant sequence increase simultaneously)
The PCR reaction system:
The PCR reaction conditions:
Step temperature-time cycle index
Pre-95 ℃ of 5min 1 of sex change
95 ℃ of 30sec of sex change
60 ℃ of 30sec 30 of renaturation
Extend 72 ℃ of 45sec
Extend 72 ℃ of 10min 1 at last
Three, hybridization and last machine testing
(1) will be coated with 19 exon wild-type probe (E19w-P), 19 exon del E746-A750 (1) mutant probes (E19m-P), 19 exon del E746-A750 (2) mutant probes (E19m-P11), 21 exon wild-type probe (E21w-P), 21 exons mutation type probes (E21m-P), the microballoon of negative control probe (N-P) is vortex 30s respectively, supersound process 30s;
(2) contain the mixing microballoon working fluid that is coated with probe with 1.5 * Tm hybridization solution preparation, make that every kind of microballoon concentration is 75/μ l in the solution;
(3) will mix microballoon working fluid vortex 30s, supersound process 30s;
(4) every hole adds 33 corresponding μ l mixing microballoon working fluids, makes and finally contains each about 2500 of every kind of microballoons in the reaction system;
(5) the background hole adds 17 μ l TE (pH8.0); Other every holes add second of 19 exons of each sample and 21 exons respectively and take turns each 2-17 μ l of PCR product, add TE to 17 μ l; Mixing gently; Covering Sptting plate (pipe lid) avoids evaporating;
(6) PCR instrument program is set: 95 ℃ of 5min; 15min is hatched in 60 ℃ of hybridization;
(7) with 1 * Tm hybridization solution preparation SA-PE to 2ug/ml (75 μ l/ hole);
(8) with reaction tubes (plate) 12, the centrifugal 5min of 000g, careful abandoning supernatant.Perhaps be transferred in the filter plate, suction filtration is removed liquid;
(9) every hole adds 75 μ l SA-PE (streptavidin phycoerythrin) working fluid (SA-PE that contains 150ng), mixings gently;
(10) place hybridization temperature (60 ℃), hatch 5min at once;
(11) the Luminex instrument is set to hybridization temperature, reading.
Four, detected result and data analysis
The reaction after product is by Luminex serial analysis instrument detecting, and detected result is as shown in table 1.There are not cross reaction in 19 exon wild-types and mutant (disappearance) probe, therefore with mutant fluorescent value (two kinds of mutant fluorescent value the higher person) divided by negative control fluorescent value (being M/N) 25 as positive decision content (cut-off value).As 19 exon detected result M/N〉25 the time, then judge this sample for there being the disappearance of 19 exons, otherwise judge that this sample is 19 exon wild-types.There are cross reaction (cross reacting rate is in 10%) in 21 exon wild-type probe and mutant probe, therefore, with (mutant fluorescent value-negative control fluorescent value)/(wild-type fluorescent value-negative control fluorescent value) i.e. ((M-N)/(W-N))〉2 as positive decision content (cut-off value).As 21 exon detected results ((M-N)/(W-N))〉2 the time, judge that there is the L858R point mutation of 21 exons in this sample, otherwise judge that this sample is 21 exon wild-types.
According to this criterion, 10 increments that present embodiment detected are in this, and there is the disappearance (No. 3, No. 5, No. 7 samples) of 19 exons in 3 examples, and there are the point mutation (No. 2, No. 10 samples) of 21 exons in 2 examples.Detected result and traditional polyacrylamide gel electrophoresis carry out the result that silver dyes again makes comparisons, and calculates the rate of coincideing.The detection rate of coincideing that the detection of the 19 exons rate of coincideing reaches 100%, 21 exon also reaches 90%.The whole rate of coincideing is 95%.Therefore, use EGFR gene mutation detection liquid-phase chip provided by the present invention and detection method thereof can accurately detect the deletion mutantion of EGFR gene 19 exons and the point mutation of 21 exons, accuracy rate is up to 95%, be the assessment Gefitinib, strategic point sieve is for the validity of targeted drugs such as Buddhist nun treatment, be convenient to clinical accurate medication, avoid the timeliness loss and the financial loss of unnecessary treatment that important detection means is provided.
The detected result of table 1 serum sample
Sequence number |
Negative control |
E19w |
E19m1 |
E19m2 |
E21w |
E21m |
NO. |
(MFI) |
(MFI) |
(MFI) |
(MFI) |
(MFI) |
(MFI) |
1 |
13 |
1751 |
70 |
56 |
189 |
21 |
2 |
14 |
1366.5 |
39.5 |
49 |
40 |
1299 |
3 |
9 |
1373 |
1593.5 |
29.5 |
194 |
23 |
4 |
7 |
1132 |
40 |
36.5 |
69 |
75.5 |
5 |
4 |
236 |
53 |
1876.5 |
154.5 |
21.5 |
6 |
10.5 |
656 |
51.5 |
54 |
38 |
31 |
7 |
19 |
661.5 |
1818 |
78 |
61 |
99 |
8 |
4 |
83 |
91 |
38 |
71.5 |
58.5 |
9 |
15 |
46 |
9 |
7.5 |
35 |
38.5 |
10 |
11.5 |
1169 |
48.5 |
29 |
189 |
412 |
Table 2 serum sample EGFR mutation type analytical results
Catalogue number(Cat.No.) |
Mutant fluorescent value/negative control fluorescent value (M/N) |
(mutagenicity fluorescent value-negative control fluorescent value)/(wild-type fluorescent value-negative control fluorescent value ((M-N)/(W-N)) |
The mutation type analytical results |
The detected through gel electrophoresis analytical results |
|
19 exons |
21 exons |
|
|
1 |
5.38 |
0.05 |
Wild-type |
Wild-type |
2 |
3.50 |
49.42 |
21 exon point mutation |
21 exon point mutation |
3 |
177.06 |
0.08 |
19 Exon deletion |
19 Exon deletion |
4 |
5.71 |
1.10 |
Wild-type |
Wild-type |
5 |
469.13 |
0.12 |
19 Exon deletion |
19 Exon deletion |
6 |
5.14 |
0.75 |
Wild-type |
Wild-type |
7 |
95.68 |
1.90 |
19 Exon deletion |
19 Exon deletion |
8 |
22.75 |
0.81 |
Wild-type |
Wild-type |
9 |
0.60 |
1.18 |
Wild-type |
Wild-type |
10 |
4.22 |
2.26 |
21 exon point mutation |
Wild-type |
Embodiment 3
The liquid-phase chip of the EGFR detection in Gene Mutation among the utilization embodiment 1 is to the detection of cancerous lung tissue sample
The cancerous lung tissue sample of getting used patient 1-10 of the foregoing description 2 detects, and detailed process is as follows:
One, the preparation of sample to be tested
The extraction of DNA in the cancerous lung tissue sample: get the tissue sample 5-50mg of lung cancer postoperative or biopsy, after the grinding, the PBS solution washing of usefulness pH7.4 2 times; Tissue sample after the washing is resuspended in Digestive system (50mmol/L Tris, the 1mmo/LNa of 1ml
2EDTA, 0.5% Tween-20, the Proteinase K 200 of 200ug/ml, pH8.5), 55 ℃ of water-baths digested 99 ℃ of water-bath 15min inactivated proteases K 1 hour; 12000 rev/mins centrifugal 10 minutes; Get supernatant, by phenol-chloroform-primary isoamyl alcohol method extracting, ethanol precipitation obtains to be used for the DNA sample of PCR reaction.Also can extract DNA by microcentrifugation post method;
Two, the pcr amplification of testing sample and enzyme are cut enrichment:
Concrete grammar is with embodiment 2.
Three, hybridization and last machine testing:
Concrete grammar detects with embodiment 2.
Four, detected result and data analysis
The reaction after product is by Luminex serial analysis instrument detecting, shown in detected result such as the table 3, table 4.Criterion is described with embodiment 2.Experimental result shows that the analytical results of cancerous lung tissue pattern detection is consistent with the result who carries out check and analysis with serum sample, i.e. the deletion mutantion (No. 3 of existence 3 examples 19 exons in the 10 routine samples, No. 5, No. 7 samples), there is the point mutation (No. 2, No. 10 samples) of 2 examples, 21 exons.Illustrate that method of carrying out the EGFR detection in Gene Mutation with free serum nucleic acid provided by the present invention is feasible, illustrate that also method provided by the present invention is reliable and stable.
The detected result of table 3 cancerous lung tissue sample
Sequence number NO. |
Negative control (MFI) |
E19w (MFI) |
E19m1 (MFI) |
E19m2 (MFI) |
E21w (MFI) |
E21m (MFI) |
1 |
15 |
1987 |
77 |
54 |
201 |
41 |
2 |
10 |
1421 |
41 |
47 |
45 |
1412 |
3 |
9 |
1405 |
1657.5 |
36 |
231 |
35 |
4 |
8 |
1387 |
39 |
25.5 |
62.5 |
84.5 |
5 |
6 |
321 |
65.5 |
1905.5 |
275 |
51 |
6 |
12 |
761.5 |
84 |
62 |
42 |
54 |
7 |
5 |
657 |
1854 |
81 |
55 |
76 |
8 |
9 |
91 |
132 |
36.5 |
81 |
73.5 |
9 |
13 |
41 |
17 |
11 |
56 |
51 |
10 |
12.5 |
1241.5 |
53.5 |
34 |
215 |
451 |
Table 4 cancerous lung tissue sample EGFR mutation type analytical results
Catalogue number(Cat.No.) |
Mutant fluorescent value/negative control fluorescent value (M/N) |
(mutant fluorescent value-negative control fluorescent value)/(wild-type fluorescent value-negative control fluorescent value ((M-N)/(W-N)) |
The mutation type analytical results |
|
19 exons |
21 exons |
|
1 |
5.13 |
0.14 |
Wild-type |
2 |
4.70 |
40.06 |
21 exon point mutation |
3 |
184.17 |
0.12 |
19 Exon deletion |
4 |
4.88 |
1.40 |
Wild-type |
5 |
317.58 |
0.17 |
19 Exon deletion |
6 |
7.00 |
1.40 |
Wild-type |
7 |
370.80 |
1.42 |
19 Exon deletion |
8 |
14.67 |
0.90 |
Wild-type |
9 |
1.31 |
0.88 |
Wild-type |
10 |
4.28 |
2.17 |
21 exon point mutation |
Embodiment 4
One, the liquid-phase chip of preparation EGFR detection in Gene Mutation
According to the method for embodiment 1 with the probe bag by microballoon:
One, the EGFR sudden change detects other alternative probe design and microballoon bag quilt
At the wild-type and the mutant sequence of EGFR gene 19,21 exons, design two groups of oligonucleotide probes (E19w-P1, E19m-P1, E19m-P13, E21w-P1, E21m-P1 and E19w-P2, E19m-P2, E19m-P12, E21w-P2, E21m-P2).5 ' end of probe is an amino group, then is the spacerarm of 10 T.Probe is synthetic by Shanghai Sangon Biological Engineering Technology And Service Co., Ltd.Probe is coupled at (bag is by process) with the microballoon (available from Luminex company) of different colours coding by covalent attachment respectively, and is described with embodiment 1.Probe sequence is as shown in the table:
The liquid-phase chip of the EGFR detection in Gene Mutation of present embodiment includes:
Be coated with SEQ ID NO.2's, microballoon at the amido modified probe of wild-type of Exon19 exon, be coated with SEQID NO.5's, microballoon at the amido modified probe of mutant of Exon19 exon del E746-A750 (1), be coated with SEQ ID NO.30's, microballoon at the amido modified probe of mutant of Exon19 exon del E746-A750 (2), be coated with microballoon at the amido modified probe of wild-type of Exon21 exon in SEQ ID NO.8, with the microballoon at the amido modified probe of mutant of Exon21 exon that is coated with SEQ IDNO.11, above-mentioned every kind of microballoon has the different colours coding; And
The primer sequence of SEQ ID NO.13-15 and SEQ ID NO.16-18, wherein 5 ' of SEQ ID NO.15 and SEQ IDNO.17 base sequence end adds biotin labeling respectively.
Two, the liquid-phase chip of the EGFR detection in Gene Mutation of present embodiment is used for the detection of lung cancer serum sample
Utilization E19w-P1, E19m-P1, E19m-P13, E21w-P1, the microballoon of E21m-P1 probe bag quilt is to the detection of nonsmall-cell lung cancer serum sample.
Select 1-5 used among the embodiment 2 totally five parts of nonsmall-cell lung cancer serum samples detect.The preparation of sample to be tested, the pcr amplification and the enzyme of sample to be tested are cut enrichment, and hybridization is described with embodiment 2 with the experimental procedure of last machine testing.Experimental result is as follows:
The detected result of table 5 serum sample
Sample |
Negative control (MFI) |
E19w-P1 (MFI) |
E19m-P1 (MFI) |
E19m-P13 (MFI) |
E21w-P1 (MFI) |
E21m-P1 (MFI) |
1 |
19 |
1695 |
85.5 |
44 |
192 |
25 |
2 |
14 |
1409 |
51 |
57 |
41 |
1305 |
3 |
13 |
1327 |
1421 |
36 |
201 |
31 |
4 |
10 |
1052 |
39 |
41 |
63 |
81 |
5 |
15 |
259 |
54 |
1881 |
167 |
23 |
Table 6 serum sample EGFR mutation type analytical results
Sample |
Mutant fluorescent value/negative control fluorescent value (M/N) |
(mutagenicity fluorescent value-negative control fluorescent value)/(wild-type fluorescent value-negative control fluorescent value ((M-N)/(W-N)) |
The mutation type analytical results |
1 |
4.50 |
0.03 |
Wild-type |
2 |
4.07 |
47.81 |
21 exon point mutation |
3 |
109.31 |
0.10 |
19 Exon deletion |
4 |
4.10 |
1.34 |
Wild-type |
5 |
125.40 |
0.05 |
19 Exon deletion |
Experimental result shows, probe E19w-P1, E19m-P1, E19m-P13, E21w-P1, E21m-P1 can be used for the sudden change of clinical sample EGFR is detected equally, analytical results and usefulness probe (E19w-P, E19m-P, E19m-P11, E21w-P, E21m-P) unanimity as a result of Jian Ceing.
Embodiment 5
One, the liquid-phase chip of preparation EGFR detection in Gene Mutation
The preparation method is with embodiment 1.
The liquid-phase chip of the EGFR detection in Gene Mutation of present embodiment includes:
Be coated with SEQ ID NO.1's, microballoon at the amido modified probe of wild-type of Exon19 exon, be coated with SEQID NO.4's, microballoon at the amido modified probe of mutant of Exon19del E746-A750 (1), be coated with SEQ IDNO.29's, microballoon at the amido modified probe of mutant of Exon19 exon del E746-A750 (2), be coated with microballoon at the amido modified probe of wild-type of Exon21 exon in SEQ ID NO.7, with the microballoon at the amido modified probe of mutant of Exon21 exon that is coated with SEQ ID NO.10, above-mentioned every kind of microballoon has the different colours coding; And
The primer sequence of SEQ ID NO.13-15 and SEQ ID NO.16-18, wherein 5 ' of SEQ ID NO.15 and SEQ IDNO.17 base sequence end adds biotin labeling respectively.
Two, the liquid-phase chip of the EGFR detection in Gene Mutation of present embodiment is used for the detection of lung cancer serum sample
Utilization E19w-P2, E19m-P2, E19mP12, E21w-P2, the microballoon of E21m-P2 probe bag quilt is to the detection of nonsmall-cell lung cancer serum sample
Totally five nonsmall-cell lung cancer serum samples of same selection 1-5 detects.The preparation of sample to be tested, the pcr amplification and the enzyme of sample to be tested are cut enrichment, and hybridization is described with embodiment 2 with the experimental procedure of last machine testing.Experimental result is as follows:
The detected result of table 7 serum sample
Sample |
Negative control (MFI) |
E19w-P2 (MFI) |
E19m-P2 (MFI) |
E19m-P12 (MFI) |
E21w-P2 (MFI) |
E21m-P2 (MFI) |
1 |
11 |
1795 |
74 |
62 |
175 |
33.5 |
2 |
17 |
1329 |
43 |
53 |
51 |
1276 |
3 |
15 |
1346 |
1542 |
33 |
187 |
41 |
4 |
10 |
1075 |
47 |
47 |
52 |
84 |
5 |
15 |
241 |
59 |
1796 |
139 |
27 |
Table 8 serum sample EGFR mutation type analytical results
Sample |
Mutant fluorescent value/negative control fluorescent value (M/N) |
(mutagenicity fluorescent value-negative control fluorescent value)/(wild-type fluorescent value-negative control fluorescent value ((M-N)/(W-N)) |
The mutation type analytical results |
1 |
6.73 |
0.14 |
Wild-type |
2 |
3.12 |
37.03 |
21 exon point mutation |
3 |
102.80 |
0.15 |
19 Exon deletion |
4 |
4.70 |
1.76 |
Wild-type |
5 |
119.73 |
0.10 |
19 Exon deletion |
Experimental result shows, probe E19w-P2, E19m-P2, E19m-P12, E21w-P2, E21m-P2 also can be used for the sudden change of clinical sample EGFR is detected analytical results and probe (E19w-P, E19m-P, E19m-P11, E21w-P, E21m-P) unanimity as a result of Jian Ceing.
<110〉Guangzhou Yishan Biotechnology Co., Ltd.
<120〉detection probes of EGFR gene mutation site, liquid-phase chip and detection method thereof